<DOC>
	<DOCNO>NCT00003004</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy paclitaxel cisplatin plus flavopiridol treating patient refractory recurrent solid tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Refractory Recurrent Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose flavopiridol administer combination paclitaxel cisplatin patient refractory adult solid tumor . II . Investigate clinical pharmacokinetics intravenous flavopiridol administer combination paclitaxel patient . III . Obtain preliminary data therapeutic activity flavopiridol administer combination paclitaxel patient . IV . Evaluate surrogate marker activity inhibition PKC CDK1 patient . OUTLINE : This open label , dose escalation study . Patients receive paclitaxel IV 3 hour day 1 . On day 2 , patient receive cisplatin IV 20 minute follow 24 hour infusion flavopiridol . Courses repeat every 21 day absence disease progression unacceptable toxicity . Sequential dose escalation flavopiridol follow sequential dose escalation cisplatin . Dose escalation cohort 3-6 patient continue maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow every 6 week . PROJECTED ACCRUAL : Approximately 46-73 patient accrue study within 6 month .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven solid tumor refractory recurrent No CNS primary metastatic disease PATIENT CHARACTERISTICS : Age : 18 Performance Status : Karnofsky least 60 % Hematopoietic : WBC least 3,500/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL AST ALT great 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL Cardiovascular : At least 6 month since prior cardiac arrhythmia , myocardial infarction , congestive heart failure Other : Not pregnant nursing Effective contraceptive method must use 2 month study completion Not HIV positive No uncontrolled serious infection No preexisting grade 3 great neurotoxicity Must mentally capable understanding explanation study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy Surgery : Not specify Other : No presence toxic effect prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>